IMC Immuron

Immuron achieves record Travelan® sales

Immuron achieves record Travelan® sales

Highlights:

  • Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 million
  • Australian Travelan® YTD Jan 2024 sales $2.1 million
  • USA Travelan® YTD Jan 2024 sales $0.6 million
  • Canadian sales recommenced through McKesson

MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Australia

Sales of Travelan® increased to AUD $2.1 million YTD Jan 2024 compared to AUD $0.3 million YTD Jan 2023.

Australian Bureau of Statistics: short term resident returns in November 2023 were 31% higher than November 2022 1.

1. 

USA

Sales of Travelan® increased to AUD $0.6 million YTD Jan 2024 compared to AUD $0.3 million YTD Jan 2023.

International Trade Administration Total U.S. citizen international visitor departures from the United States in November 2023 were 11% higher than in November 2022. 2

2. .

Canada

Immuron have recommenced Travelan® sales in Canada through McKesson.

Flavio Palumbo, Chief Commercial Officer said, “We are excited by the strong sales results on Travelan®. Immuron’s investment to drive awareness of the Travelan® brand has seen strong sales results in Australia over the summer peak travel period. We hope to get similar growth of the brand as we increase our investment and distribution in North America during the spring / summer vacation peak period.”

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT:

Steven Lydeamore

Chief Executive Officer

Ph: +61 (0)3 9824 5254

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information visit:  



EN
13/02/2024

Underlying

IMCImmuron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immuron

 PRESS RELEASE
Free
IMC IMMURON

Immuron New U.S. Department of Defense Award & Clinical Trial Update

Immuron New U.S. Department of Defense Award & Clinical Trial Update Highlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and ShigellaUniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announces a new research agreement with the Naval Medical Research Command (NMRC) and the Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA funded by a U.S....

December 3, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron IMM-529 IND approved by FDA

Immuron IMM-529 IND approved by FDA Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceedFDA assigned an IND number (032095) for the IMM-529 application IND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) and is now active MELBOURNE, Australia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Announces Clinical Trial Update

Immuron Announces Clinical Trial Update IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data delayed to the end of November due to U.S government shutdown MELBOURNE, Australia, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company provides a clinical trial update on Travelan® and IMM-529. IMM-529 IND (Clostridioides difficile infection)Immuron announced ...

October 31, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Q1 FY26 YoY growth

Immuron Q1 FY26 YoY growth Sales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)   Australia•Q1 sales AUD$1.6 million up 52% on pcp   Canada•Q1 sales AUD$0.0 million down 92% on pcp   USA•Q1 sales AUD$0.4 million up 44% on pcp MELBOURNE, Australia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and th...

October 13, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Submits IMM-529 IND to FDA

Immuron Submits IMM-529 IND to FDA Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 MELBOURNE, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for clinical developm...

October 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch